Due to the specificity of HPV-induced HNSCC in clinical manifestations and response to treatment, there are significant differences in tumor immune microenvironment among HNSCC patients based on HPV infection status, thus the ORRs to PD-1/PD-L1 blockade are also different. The gene discussed is CD274; the disease is neoplasm.